Sanofi-Aventis May Be First In Wave Of National Pharma; Will Swiss Follow?
Executive Summary
Sanofi-Synthelabo's merger with Aventis may be the first in a trend towards the creation of national pharma companies that could include the formation of "Pharma Swiss," according to Wood Mackenzie VP-Life Sciences Clifford Kalb
You may also be interested in...
GSK’s travel plans, or lack thereof
GlaxoSmithKline responds to an article in 1"The Pink Sheet" (April 3, 2006, p. 8) discussing international mergers. "The article quotes comments made by Clifford Kalb, VP of Life Sciences at Wood Mackenzie, speculating on future mergers expected in the pharmaceutical industry," GSK notes. "Among those comments, the article references Mr. Kalb as saying that GlaxoSmithKline's CEO 'recently visited the offices of New Jersey Governor Jon Corzine seeking a tax break to relocate the firm's headquarters.' Mr. Kalb's speculation is completely wrong. The company's CEO has not met with Governor Corzine, and GlaxoSmithKline has no intention of moving its headquarters from the UK to the U.S.," GSK says...
Pharma M&A: An Unattractive But Inevitable Reality?
Pharmaceutical industry mergers have not been a source of sustainable competitive advantage, Wood Mackenzie VP-Life Sciences Clifford Kalb said during the Special Libraries Association Pharmaceutical & Health Technology Division Spring Meeting in Memphis March 28
Pharma M&A: An Unattractive But Inevitable Reality?
Pharmaceutical industry mergers have not been a source of sustainable competitive advantage, Wood Mackenzie VP-Life Sciences Clifford Kalb said during the Special Libraries Association Pharmaceutical & Health Technology Division Spring Meeting in Memphis March 28